R&D Portfolio

Our portfolio of wholly-owned assets includes a pipeline focused on curing HBV and treating coronavirus infections (including COVID-19).  A combination of products that reduce surface antigen, suppress viral replication, and boost the immune system are needed to achieve an HBV cure.